 |
|
Malignant MelanomaTreatment With High-Dose Combination Alkylating Agent Chemotherapy and Autologous Bone Marrow Support
Thomas C. Shea, MD;
Karen H. Antman, MD;
J. Paul Eder, MD;
Anthony Elias, MD;
William P. Peters, MD, PhD;
Susan Schryber, RN;
William D. Henner, MD, PhD;
David A. Schoenfeld, PhD;
Lowell E. Schnipper, MD;
Emil Frei III, MD
Arch Dermatol. 1988;124(6):878-884.
Abstract
| |
• Nineteen patients with metastatic malignant melanoma were treated with 20 courses of high-dose combination alkylating agent chemotherapy and autologous bone marrow support. All 20 treatment courses were evaluable for toxic reactions and 17 of 20 were assessable for response. Twelve of the 20 courses were given at the phase 2 dose per square meter of cyclophosphamide (5.625 g), cisplatin (165 mg), and carmustine (600 mg). Marrow reconstitution occurred with a median time to recovery of 21 and 24 days for more than 500 neutrophils and more than 20 000 platelets, respectively. The overall response rate was 65%, with one patient achieving a complete response with chemotherapy alone. Ten additional patients achieved partial responses following chemotherapy, of which three were subsequently rendered disease free by surgical resection of single areas of residual tumor. Two of these patients are alive and disease free more than 22 months following chemotherapy and one remains relapse free. The median survival for responding patients was 15.2 months and 8.6 months for the entire group.
(Arch Dermatol 1988;124:878-884)
Author Affiliations
From the Department of Medicine, Dana-Farber Cancer Institute and Dana Research Institute, Division of Medical Oncology, Department of Medicine, Beth Israel Hospital, and Harvard Medical School, Boston. Dr Peters is now with Duke University Medical Center, Durham, NC.
Footnotes
Accepted for publication Nov 30, 1987.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
